Thus, it is possible that the aberrant expression of IL-1Ra in cancer cells inhibits the anti-tumor role of IL-1β in APC-mediated T cell activation, thereby contributing to a subtype of gemcitabine, or other types of chemotherapies, resistant PDA. This evidence concerns the gene IL1B and Patent ductus arteriosus.